Main Article Content



Momordicacharantia commonly known as Karela is widely known for its medicinal properties. Its Antidepressant activity is least evaluated. Depression being common psychiatric illness of all age groups. Currently available Antidepressants have their own limitations. The antidepressant activity of MomordicaCharantia leaves was evaluated in this study.


The aim of this study is to evaluate the Antidepressant activity of Methanolic extract of MomordicaCharantia leaves.


This study was done in Department of Pharmacology, JNMC, AMU. Antidepressant activity of MEMC (Methanolic extract of MomordicaCharantia leaves) . at doses of 100mg/kg, 200 mg/kg and 300 mg/kg was evaluated in Swiss Albino mice and Albino Wistar rats in Tail suspension test, Forced swim test, Spontaneous motor activity, Learned helplessness test and 5-Hydroxytryptophan induced Head Potentiation tests.


MEMC exhibited antidepressant activity by significantly decreasing the immobility time in Tail Suspension test in all doses and in doses of 200 mg/kg and 300 mg/kg in Forced swim test. No significant increase in Spontaneous motor activity was seen in all three doses ruling out psychostimulant activity. In Learned Helplessness test number of Escape failures was decreased at doses of MEMC 200 mg/kg and 300 mg/kg. Increase in Head twitches was seen in both MEMC 200 mg/kg and 300 mg/kg in 5-Hydroxytrytophan induced Head Potentiation in mice.


Antidepressant activity was exhibited by Methanolic extract of MomordicaCharantia leaves in animal models of Depression.


Depression Momordicacharantia Tail suspension test Forced swim test Learned Helplessness test 5-Hydroxytrytophan induced Head Potentiation in mice

Article Details

How to Cite
A Haseeb, F Ahmad, & A Kumar. (2021). An experimental study on antidepressant activity of methanolic extract of momordica charantia leaves. International Journal of Research in Pharmacology & Pharmacotherapeutics, 7(4), 327-335. Retrieved from


  1. [1]. Tarkang PA, Ofogba CJ. Evaluation of the Hypoglycemic Activity and Safety of Momordicacharantia (Cucurbitaceae). African Journal of Pharmaceutical Sciences and Pharmacy, 3(1), 2012, 17-29.
  2. [2]. Kubola J, Siriamornpun S. Phenolic contents and antioxidant activities of bitter gourd (Momordicacharantia L.) leaf, stem and fruit fraction extracts in vitro. Food Chemistry. 110, 2008, 881–890.
  3. [3]. Chaudhari BP, Chaware VJ, Joshi YR, Biyani KR. Hepatoprotective activity of Hydroalcoholic extract of Momordicacharantia Linn. leaves against Carbon tetrachloride induced Hepatopathy in Rats. International Journal of ChemTech Research. 1(2), 2009, 355-358.
  4. [4]. Chaware VJ, Chaudhari BP, Joshi YR, Biyani KR. Protective Effect of the Aqueous Extract of Momordicacharantia Leaves on Gentamicin Induced Nephrotoxicity in Rats. 3(1), 2011 Jan-Mar, 553-555.
  5. [5]. Sethi P. Momordicacharantia L- AnEthnobotanical drug. International Journal of Pharma and Bio Sciences. 3(2), 2012 1-5.
  6. [6]. Waiyaput W, Payungporn S, Issara-Amphorn J, Panjaworayan NT. Inhibitory effects of crude extracts from some edible Thai plants against replication of hepatitis B virus and human liver cancer cells. BMC Complement Altern Med. 12, 2012 246.
  7. [7]. Ganesan A. Natesan S. Perumal PG. Vellayutham R. Manickam K. Ramasamy N. Anxiolytic, Antidepressant and Anti- inflammatory activities of Methanol extract of MomordicacharantiaLinn. Leaves (Cucurbitaceae). Iranian Journal of Pharmacology and Therapeutics. 7, 2008, 43.
  8. [8]. World Health Organization. The World health report: Mental health: new understanding, new hope. Geneva, 2001. Accessed on 2012.
  9. [9]. Revised global burden of disease (GBD) 2002 estimates. Geneva, World Health Organization, 2005. Accessed on 2012.
  10. [10]. O'Donnell JM, Shelton RC. Drug Therapy of Depression and Anxiety Disorders. Brunton LL, Chabner BA, and Knollman BC, Eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics. The McGraw-Hill Companies, New York, USA, 12, 2011, 397-412.
  11. [11]. Nutt DJ. Treatment of Depression. Bennet PN and Brown MJ, Eds., Clinical Pharmacology. Churchill Livingston, Philadelphia, USA, 10, 2008, 331-341.
  12. [12]. Reus VI. Mental Disorders. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalo J, Eds., Harrison’s Principle of internal medicine. The McGraw-Hill Companies, New York, USA, 18, 2012, 3536-37.
  13. [13]. Salawu OA, Ezekiel EO, Adaudia O, Kwanashie HO. Toxicological evaluation of Methanolic extract of Momordicacharantia leaves in rats. West Afr. J. Pharmacol. Drug Res. 20(1), 2004, 15-21.
  14. [14]. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology. 85, 1985, 367–370.
  15. [15]. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressive treatments. Eur J Pharmacol. 47, 1978, 379–391.
  16. [16]. Boissier JR, Simon P. Action of caffeine on the spontaneous motility of the mouse. Arch IntPharmacodynTher. 158, 1965, 212–21.
  17. [17]. Porsolt RD, Martin P, Lenègre A, Fromage S, Drieu K. Effects of an extract of Ginkgo biloba (EGB 761) on “learned helplessness” and other models of stress in rodents. PharmacolBiochemBehav. 36, 1990, 963–971.
  18. [18]. Vogel HG. Drug Discovery and Evaluation Pharmacological Assay Second Edition. Springer-Verlag Berlin Heidelberg, 2002, 570.
  19. [19]. Rang HP, Dale MM, Ritter JM, Flower RJ. Antidepressant drugs.In: Rang HP, Dale MM, Ritter JM, Flower JM. Rang and Dale’s Pharmacology. Churchill Livingstone, 6, 2009, 563.
  20. [20]. Krishnan V, Nestler EJ. The Molecular Neurobiology of Depression. Nature. 455, 2008, 894-902.
  21. [21]. Sherman AD, Allers GL, Petty F, Henn FA. A neuropharmacologically- relevant animal model of depression. Neuropharmacol. 18, 1979, 891–893.
  22. [22]. Rang HP, Dale MM, Ritter JM, Flower RJ. Other transmitters and modulators. Rang and Dale’s Pharmacology. 6th edition. Churchill Livingstone Publications, 2009, pp 499.
  23. [23]. Pemminati S, Gopalakrishna HN, Shenoy AK, Sahu SS, Mishra S, Meti V, Vinod N. Antidepressant activity of aqueous extract of fruits of EmblicaOfficinalis in mice. International Journal of Applied Biology and Pharmaceutical Technology. 1(2), 2010, 449-454.
  24. [24]. Chhillar R, Dhingra D. Antidepressant-like activity of gallic acid in mice subjected to unpredictable chronic mild stress. FundamClinPharmacol. 27(4), 2013, 409-18.
  25. [25]. Rocha FF, Lima-Landman MTR, Souccar C, Tanae MM, De Lima TCM, Lapa, Antidepressant-like effect of CecropiaglaziouiSneth and its constituents – In vivo and in vitro characterization of the underlying mechanism. Phytomedicine. 14, 2007, 396-402.
  26. [26]. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and human health: an update. Arch Toxicol. 86(4), 2012, 521-34.
  27. [27]. Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, Pilc A, Nowak G. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord. 118, 2009, 187–195.
  28. [28]. Hall NT, Nagy S, Berry RE. Leaves for Food: Protein and Amino acid contents of leaves from 23 Tropical and Subtropical plants. Florida state Horticultural Society. 1975, 486-490.
  29. [29]. Zhang M, Hettiarachchy NS, Horax R, Chen P, Over KF. Effect of maturity stages and drying methods on the retention of selected nutrients and phytochemicals in bitter melon (Momordicacharantia) leaf. J Food Sci. 74(6), 2009, 441-8.
  30. [30]. Aggarwal A, Gaur V, Kumar A. Nitric oxide mechanism in the protective effect of naringin against post-stroke depression (PSD) in mice. Life Sci. 86(25-26), 2010, 928-35.
  31. [31]. Herrera-Ruiz M, Zamilpa A, González-Cortazar M, Reyes-Chilpa R, León E , García MP, Tortoriello J, Huerta-Reyes M. Antidepressant effect and pharmacological evaluation of standardized extract of flavonoids from Byrsonimacrassifolia. Phytomedicine. 18, 2011, 1255– 1261.